Myriad Genetics Inc. 10-Q Summary: Quarter Ended December 31, 1998
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1998, and the six months ended on that date. Myriad Genetics, Inc. is a biotechnology company focused on genetic testing and collaborative research agreements. The company has been unprofitable since inception, with an accumulated deficit of $39.5 million as of the reporting date. Its primary revenue streams are payments from collaborative research agreements with pharmaceutical partners and sales of genetic diagnostic tests, most notably BRACAnalysis for breast and ovarian cancer susceptibility.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 1998 | Six Months Ended Dec 31, 1998 |
|---|---|---|
| Total Revenues | $5,747,471 | $11,307,457 |
| Net Loss | ($2,850,259) | ($5,552,761) |
| Loss Per Share (Basic/Diluted) | ($0.30) | ($0.59) |
| Operating Cash Flow | ($3,064,275) | ($7,570,474) |
| Cash and Cash Equivalents (Ending) | $17,302,845 | $17,302,845 |
| Total Assets | $59,107,466 | $59,107,466 |
| Debt (Notes Payable) | $0 | $0 |
Note: The company had no current portion of notes payable as of December 31, 1998, having paid down the balance during the period.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 13% to $5.75 million for the quarter compared to $5.09 million in the prior year quarter. This was driven by a 131% increase in genetic testing revenue ($1.21 million vs. $0.52 million), offset by a slight decline in research revenue due to the absence of a $950,000 contract expansion payment received from Bayer in the prior year.
- Expense Increases: Research and development expenses rose 13% to $5.68 million, attributed to expanded collaborations with Novartis, Bayer, Schering, and Monsanto, as well as increased personnel and equipment costs. Selling, general, and administrative expenses decreased slightly by 4% to $2.76 million as the sales force stabilized.
- Liquidity Position: Cash and cash equivalents increased by $8.1 million during the quarter. This significant increase was primarily due to a sale-leaseback transaction with General Electric Capital Corporation, where the company sold equipment for $3.55 million and leased it back, alongside a shift of marketable securities to cash equivalents.
- Investing Activities: Net cash provided by investing activities was $10.9 million, largely driven by the $3.55 million proceeds from the equipment sale and net purchases of marketable securities.
Guidance, Outlook, and Risks
Outlook: Management expects to incur losses for at least the next several years due to the expansion of research and development programs, staffing costs, and facility expansion. The company anticipates that existing capital resources will be adequate for at least the next two years but intends to raise additional funds when conditions are favorable.
New Collaborations: The company entered into significant new agreements in late 1998:
- Schering AG: A five-year collaboration utilizing ProNet technology with potential value up to $51 million.
- Monsanto: A 15-month collaboration with potential value up to $15 million.
- Bayer: An expansion of the existing agreement with potential milestone payments up to $12 million.
Risks and Contingencies:
- Year 2000 Issue: The company is in Phase II of its Y2K readiness review. While management does not expect a material effect on operations, failure to address the issue or failures by suppliers could disrupt operations, invoicing, and research efforts.
- Commercialization: There is uncertainty regarding reimbursement from government and private insurers for genetic tests and the commercial acceptance of new products.
- Competition: Intense competition exists in the discovery of disease-related genes, and the company may not secure rights to critical genes.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of the 131% growth in genetic testing revenue and the reliance on collaborative research payments which are recognized as costs are incurred.
- Cash Burn Rate: Confirm the company's ability to fund operations for the projected two-year runway given the continued net loss of approximately $2.85 million per quarter.
- Collaboration Milestones: Monitor the progress of new agreements with Schering AG and Monsanto to ensure anticipated milestone payments and royalties are realized.
- Y2K Compliance: Assess the status of the Phase II Y2K review and the readiness of key third-party suppliers to mitigate operational disruption risks.
- Asset Structure: Note the recent sale-leaseback transaction which improved immediate liquidity but created future lease obligations of approximately $3.73 million over 48 months.